World ADC San Diego 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Large pharma companies at World ADC San Diego 2026

Oct 12–15, 2026 San Diego, CA ~1.3k attendees Website

18 large pharma companies are at World ADC San Diego 2026 — 65 presentations on the program. Most represented: Merck & Co. (6 on the program), Daiichi Sankyo (5 on the program), Pfizer (4 on the program). 13 of them have their own page in this guide. As of Oct 8, 2026.

All 165 organizations at World ADC San Diego 2026 →

Showing 1–8 of 18 organizations

Organization	World ADC San Diego 2026 Attendance
Merck & Co. Rahway, NJ
merck.com Large pharma Global pharmaceutical company, known as MSD outside the US and Canada, with marketed cancer medicines and an ADC pipeline.	Panel Mon Oct 12 12:00pm Breaking Down Strategic Approaches to Ensure Product Quality in Late-Stage ADC Manufacturing Pre-conference: 8th CMC Day Talk Wed Oct 14 11:00am Harnessing Computational & Mechanistic Insights Into Chemoselective Reduction for Engineered Cysteine Site-Specific ADCs Discovery Chemistry Talk Wed Oct 14 12:00pm Assessing Case Study Characterization & Control of an ADC Variant to Mitigate Analytical Comparability Risk Process & Analytical Development Talk Wed Oct 14 2:00pm Mechanistic QSP Platform for ADCs in Oncology: Exploring Prospective Efficacy & Safety Predictions to Guide Study Design Translational Medicine Talk Wed Oct 14 3:00pm Evaluating Environmental Temperature as a Hidden Critical Factor in icIEF for a Late-Stage ADC Process & Analytical Development
Daiichi Sankyo Tokyo, Japan
daiichisankyo.com Large pharma Japanese pharmaceutical company behind the DXd ADC platform, including trastuzumab deruxtecan and datopotamab deruxtecan.	Panel Mon Oct 12 2:30pm Tackling Opportunities & Strategies to Identify High Risk Patients & Best Mitigate Clinical ADC Toxicities VIRTUAL PRESENTATION Pre-conference: 7th Toxicity Day Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Iksuda Therapeutics, Pfizer +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 2:30pm The Transition of an ADC From Late-Line to First-Line Therapy in HER2+ Breast Cancer & Earlier Line Gastric Cancer: The Trastuzumab Deruxtecan (T-DXd) Example Clinical Lessons Panel Tue Oct 13 3:30pm Assessing the Growing Importance of ADC Sequencing & Combination Approaches to Optimize Differentiated Clinical Performance Clinical Lessons Talk Wed Oct 14 2:00pm Highlighting Preclinical Development of DS-3939a, a DXd-ADC Targeting TA-MUC1 Preclinical Workshop Thu Oct 15 1:00pm Breaking Down Clinical Characterization & Differentiation Strategies to Set Up ADC Development for Success in an Increasingly Busy Oncology Landscape Post-conference workshop for Translational Medicine & Clinical Lessons · with NEOK Bio
Pfizer New York, NY
pfizer.com Large pharma Global pharmaceutical company whose oncology portfolio includes ADCs gained with Seagen, such as PADCEV.	Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Daiichi Sankyo, Iksuda Therapeutics +1 more ADC discovery chemistryADC discovery biology Talk Tue Oct 13 11:00am PF-08046033: Advancing GPNMB Targeted Auristatin-S ADC Through Payload Modification to Improve Tolerability Preclinical Talk Tue Oct 13 12:00pm Deep-Diving Into Mechanistic Insights of a Novel ADC Payload That Inhibits Protein Translation Discovery Chemistry Talk Tue Oct 13 2:00pm Setting the Scene for Novel Combination Partner Approaches for Vedotin-Based ADCs Including PADCEV – VIRTUAL PRESENTATION Clinical Lessons Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, AstraZeneca, Iksuda Therapeutics +1 more Chair Leveraging Novel Payload MoAs & Combinations to Differentiate ADC Mechanisms & Combat Patient Resistance Discovery Chemistry Panel Wed Oct 14 2:30pm What is Showing the Most Promise & What Still Needs to be Proven in ADC Chemistry & Mechanistic Innovation? Discovery Chemistry
AstraZeneca Cambridge, UK
astrazeneca.com Large pharma Global pharmaceutical company whose ADCs include trastuzumab deruxtecan and datopotamab deruxtecan, co-developed with Daiichi Sankyo.	Chair Unlocking the Therapeutic Power of Rationale-Driven ADC Combinations Pre-conference: 10th ADCs in Combination Day Talk Mon Oct 12 10:00am Addressing ADC Regulatory Strategy for Gross Content Testing, Linker RSM Definition & Alternative Charge Variant QC for Release & Stability Pre-conference: 8th CMC Day Talk Mon Oct 12 10:00am Combining the Past, Present & Future: Learnings, Trends & Impact of the Past 10 Years of ADC Combination Therapies Pre-conference: 10th ADCs in Combination Day Talk Tue Oct 13 11:00am Evaluating CMC Projects to Ensure Sustainable, Time & Cost Sensitive Manufacturing Across the ADC Product Portfolio Manufacturing & Supply Chain Talk Tue Oct 13 11:00am PROTAC ADCs: Incorporating Historical Learnings to Navigate Novel Payload Development Beyond Blind Potency Discovery Chemistry Panel Tue Oct 13 3:30pm What’s the New Path to the Next Generation of ADCs? Discovery Biology · with Sygnature Discovery, Iksuda Therapeutics, Pfizer +1 more
Regeneron Tarrytown, NY
regeneron.com Large pharma Develops and markets antibody medicines, and researches new linker-payloads and bioconjugate designs beyond classic cytotoxic ADCs.	Chair Pushing the Boundary of Novel Bioconjugate Mechanisms & Design Pre-conference: 4th Novel Conjugates Day Talk Mon Oct 12 12:00pm Spotlighting Discovery of Novel Linker Payloads to Set the Path for the Next Wave of Differentiated Antibody Conjugates Pre-conference: 4th Novel Conjugates Day Panel Mon Oct 12 3:00pm Discussing the Future of ADC Chemistry & Design to Herald a New Era of Bioconjugate Innovation Pre-conference: 4th Novel Conjugates Day Panel Tue Oct 13 8:00am Contextualizing the Current Status of Novel ADC Design & Development to Ensure Future ADC Success & Differentiated Patient Impact Plenary · with Amgen, Daiichi Sankyo, Iksuda Therapeutics +1 more ADC discovery chemistryADC discovery biology Talk Wed Oct 14 12:00pm The 18-Month Journey to Clinic for ADCs: How Operational Strategy Sets The Pace for IND Manufacturing & Supply Chain Workshop Thu Oct 15 1:00pm Beyond Traditional ADCs: Breaking Down Control Strategies for Non‑Cytotoxic Bioconjugate Modalities Post-conference workshop for Process & Analytical Development · with Bristol Myers Squibb, Gilead Sciences
AbbVie North Chicago, IL
abbvie.com Large pharma Global pharmaceutical company developing antibody-drug conjugates in oncology, including ABBV-400 for colorectal and other solid tumors.	Talk Mon Oct 12 2:00pm Assessing Immunogenic Senescence to Promote the Activity of Topo1 Inhibitor ADCs Pre-conference: 3rd Pharmacology Day · with MediLink Therapeutics Panel Mon Oct 12 2:30pm Breaking Down Learnings From Pharmacology & PD Profiles to Understand In-Depth Insights for the Next Wave of ADCs Pre-conference: 3rd Pharmacology Day Talk Tue Oct 13 12:00pm Exploring the Safety & Efficacy Profile of ABBV-400 in CRC to Assess ADC Impact in Unmet Solid Tumor Medical Need Clinical Lessons Talk Wed Oct 14 9:00am Delving Into Discovery of Pan-PI3K & mTOR Dual Inhibitors as a First-in-Class ADC Payload Plenary ADC discovery chemistry Talk Wed Oct 14 2:30pm Investigating Best Technologies & Methods to Scale Up Process From Lab to GMP Across ADC Formats Process & Analytical Development
Bristol Myers Squibb Princeton, NJ
bms.com Large pharma Global pharmaceutical company with oncology, immunology and cardiovascular medicines and a pipeline that includes bispecific ADCs.	Talk Mon Oct 12 2:30pm ADC Photosensitivity: Detailing Methodologies to Adapt Manufacturing & Site Requirements to Combat Payload-Specific Photodegradation Pre-conference: 8th CMC Day Talk Mon Oct 12 2:30pm Understanding ADC Charge Variants to Enable Effective CQA Assessment & Control Strategy Pre-conference: 2nd Analytical & CQA Day Talk Tue Oct 13 11:00am Showcasing Capability & Application of Automated HLPC to Undergo ADC Process Development Optimization Process & Analytical Development Workshop Thu Oct 15 1:00pm Beyond Traditional ADCs: Breaking Down Control Strategies for Non‑Cytotoxic Bioconjugate Modalities Post-conference workshop for Process & Analytical Development · with Regeneron, Gilead Sciences
Eli Lilly Indianapolis, IN
lilly.com Large pharma Global pharmaceutical company with an oncology pipeline that includes antibody-drug conjugates.	Chair Elevating Confident Characterization of Increasingly Complex Conjugates Pre-conference: 2nd Analytical & CQA Day Talk Mon Oct 12 10:00am Laying Out ADC CQAs & Understanding Regulatory Quality Perspectives as Complex Biologic & Small Molecule Therapies Pre-conference: 2nd Analytical & CQA Day Talk Mon Oct 12 10:30am Exploring Sofetabart Mipitecan Enhanced Anti-Tumor Activity in Combination with SoC Therapies in Ovarian Cancer Models to Support Clinical Development Pre-conference: 10th ADCs in Combination Day Workshop Thu Oct 15 9:00am Deep Diving Into CMC Best Practices to Ensure Stakeholder Alliance to Optimize ADC Production & Regulatory CMC Strategy Post-conference workshop for Manufacturing & Supply Chain · with Amgen